Agenus (NASDAQ:AGEN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

35.3% of Agenus shares are owned by institutional investors. Comparatively, 67.1% of Cidara Therapeutics shares are owned by institutional investors. 6.4% of Agenus shares are owned by insiders. Comparatively, 15.2% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Agenus and Cidara Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agenus -281.49% N/A -102.16%
Cidara Therapeutics N/A -96.55% -72.59%

Analyst Ratings

This is a summary of recent ratings and price targets for Agenus and Cidara Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus 0 0 0 0 N/A
Cidara Therapeutics 0 0 5 0 3.00

Cidara Therapeutics has a consensus price target of $13.25, indicating a potential upside of 197.75%. Given Cidara Therapeutics’ higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than Agenus.

Risk and Volatility

Agenus has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Earnings and Valuation

This table compares Agenus and Cidara Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus $42.88 million 5.65 -$120.69 million ($1.23) -1.74
Cidara Therapeutics N/A N/A -$55.72 million ($3.18) -1.40

Cidara Therapeutics has lower revenue, but higher earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.


Cidara Therapeutics beats Agenus on 8 of the 11 factors compared between the two stocks.

About Agenus

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.